Neutrophilic eccrine hidradenitis due to chemotherapy
Keywords:
neutrophilic eccrine hidradenitis, neutrophilic dermatosis, leukemia, chemotherapy, cytarabine, idarubicinAbstract
Neutrophilic eccrine hidradenitis is an infrequent and self-limiting inflammatory dermatosis that occurs, in most cases, in patients with oncohematological diseases associated to chemotherapeutic treatment. The dermatosis usually appears between 7 to 10 days after the start of chemotherapy, associated with fever. The diagnosis should be done excluding other pathologies and with the histopathological study which is characterized by an accentuated neutrophilic infiltrate within the eccrine glands. We describe 2 cases of neutrophilic eccrine hidradenitis in patients with acute leukemia under chemotherapeutic treatment and their management.References
I. Harrist TJ, Fine JD, Berman RS, Murphy GF, et ál. Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy. Arch Dermatol 1982;118:263-266.
II. Flynn TC, Harrist TJ, Murphy GF, Loss RW, et ál. Neutrophilic eccrine hidradenitis: a distinctive rash associated with cytarabine therapy and acute leukemia. J Am Acad Dermatol1984;11:584-590.
III. Córdoba AA, Moreno PF, Amaro AV, Leonardi RC. Lesiones eritematodolorosas plantares. Rev Argent Dermatol 2004;10:161-162
IV. Sánchez-Aguilar D, Rodríguez l, Flórez A, Pereiro Ferreirós M, et ál. Hidradenitis palmoplantar idiopática. Actas Dermosifiliogr 1999;90:378-388.
V. Shlapak D, Kerisit K, Lin C, Wang A, et ál. Resident rounds. Part III: Neutrophilic eccrine hidradenitis in the setting of acute myelogenous leukemia treated with cytarabine. J Drugs Dermatol 2013;12:231-232.
VI. Cohen PR. Neutrophilic dermatoses occurring in oncology patients. Int J Dermatol 2007;46:106-111.
VII. Bachmeyer C, Aractingi S. Neutrophilic eccrine hidradenitis. Clin Dermatol 2000;18:319-330.
VIII. Herms F, Franck N, Kramkimel N, Fichel F, et ál. Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event. Br J Dermatol2017;176:1645-1648.
IX. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol2008;59:524-529.
X. Shear NH, Knowles SR, Shapiro L, Poldre P. Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. J Am Acad Dermatol 1996;35:819-822.
XI. Villarreal-Villarreal CD, Ocampo-Candiani J, Villarreal-Martínez A. Sweet syndrome: a review and update. Actas Dermosifiliogr2016;107:369-378.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Argentine Society of Dermatolgy
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.
Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor
